PharmaMar/Jazz Pharmaceuticals get NDA priority for lung cancer drugPharmaMar and Jazz Pharmaceuticals have received FDA Priority Review of a NDA for lurbinectedin in relapsed SCLC (Small Cell Lung Cancer). more ➔
Diabetes combo improves regeneration of beta cellsUsing a combination of approved diabetes drugs, a Swiss-US research team was able to support the regeneration of insulin-secreting cells in the pancreas. more ➔
JAKPot for treating bone loss Researchers report that JAK inhibitors – a class of approved anti-inflammatory drugs – prevented bone loss in mice with osteoporosis and two patients with rheumatoid arthritis. more ➔
Mereo BioPharma raise money to back Phase III trialsMereo BioPharma has entered into a $5m convertible equity financing with Novartis and a $28m securities purchase agreement with Aspire Capital Fund. more ➔
Stilla raises €20m in series B financing roundFrench Stilla Technologies SA raised €20m in a Series B funding to boost digital PCR-based genetic testing. more ➔
BIH scientists optimise CRISPR gene scissorsTargeted genome editing using the CRISPR-Cas9 system is easy to use but far from being perfect. Computer calculated modification of CRISPR activity can reduce "off-target effects". more ➔
Azafaros BV raises €25m in Series A roundDutch biotech Azafaros B.V. has closed a €25m Series A financing round. more ➔
Researchers identify roots of childhood asthma Infants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children. more ➔
MaaT Pharma raise €18m to advance clinical pipeline MaaT Pharma SA has announced €18m Series B financing to boost its microbiome biotherapeutics pipeline. more ➔
Valneva raises US$85mFrench vaccine developer Valneva SA will raise $85m in a financing arrangement with Deerfield and OrbiMed and go Nasdaq to co-fund its Lyme disease programme. more ➔
